Cumberland Pharmaceuticals (CPIX) Cash & Equivalents (2010 - 2026)

Cumberland Pharmaceuticals has disclosed Cash & Equivalents across 17 years of filings, most recently posting $11.0 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $11.0 million, down 27.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.0 million (down 27.14% YoY), and the FY2025 annual result was $11.4 million, down 36.29% from the prior year.
• Cash & Equivalents came in at $11.0 million for Q1 2026 at Cumberland Pharmaceuticals, down from $11.4 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $19.8 million in Q4 2022 to a low of $11.0 million in Q1 2026.
• The 5-year median for Cash & Equivalents is $17.5 million (2024), against an average of $16.8 million.
• Across the five-year window, Cash & Equivalents grew 13.2% in 2024 and plunged 36.29% in 2025, its largest moves.
• Cumberland Pharmaceuticals' Cash & Equivalents stood at $19.8 million in 2022, then dropped by 7.27% to $18.3 million in 2023, then declined by 1.95% to $18.0 million in 2024, then slumped by 36.29% to $11.4 million in 2025, then dropped by 3.82% to $11.0 million in 2026.
• The last three Cash & Equivalents figures came in at $11.0 million (Q1 2026), $11.4 million (Q4 2025), and $15.2 million (Q3 2025), per Business Quant data.